Related Experiment Video
Updated: Jun 24, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Insulin pump therapy: guidelines for successful outcomes.
Gary Scheiner1, Robert J Sobel2, Daphne E Smith3
1The Integrated Diabetes Services, Wynnewood, Pennsylvania (Mr Scheiner)
The Diabetes Educator
|March 26, 2009
Summary
Insulin pump therapy, or continuous subcutaneous insulin delivery (CSII), offers precise dosing for better diabetes management. Technological advancements and insurance coverage are making this advanced diabetes treatment more accessible and appealing.
Area of Science:
- Endocrinology
- Medical Devices
- Diabetes Management
Background:
- Current insulin delivery methods include syringes, pens, and insulin pumps.
- Insulin pump therapy (CSII) provides precise and flexible insulin dosing.
- Technological advancements have enhanced the appeal and accessibility of insulin pumps.
Purpose of the Study:
- To describe the rationale for insulin pump therapy.
- To outline the potential advantages and disadvantages of CSII.
- To discuss strategies for patient selection and education in insulin pump therapy.
Main Methods:
- Review of current literature on insulin pump therapy.
- Analysis of technical and software advancements in insulin pumps.
- Discussion of patient education and management strategies.
Main Results:
- Insulin pumps offer improved glycemic control and reduced diabetes complication risks.
- Modern insulin pumps are discreet, ergonomic, and water-resistant.
- Smart pump features and data analysis software provide enhanced diabetes management insights.
Conclusions:
- Successful insulin pump therapy requires comprehensive patient education and glucose monitoring.
- Expanded insurance reimbursement has increased access to CSII.
- Diabetes educators play a key role in optimizing patient outcomes with insulin pump therapy.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment: